Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536712 | 0.85 | MAPT (0.53) | MAPTHTTLMNANPC1MEN1 | |
| SCHEMBL27708738 | 0.85 | KDM4E (0.54) | MAPTHTTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL30601243 | 0.84 | CD38 (0.41) | MAPTHTTLMNATP53MEN1 | |
| SCHEMBL30601234 | 0.84 | CD38 (0.41) | MAPTHTTLMNATP53MEN1 | |
| SCHEMBL1536687 | 0.84 | SMN1; SMN2 (0.51) | MAPTLMNANPC1SMN1; SMN2MEN1 | |
| SCHEMBL30601246 | 0.81 | ALDH1A1 (0.44) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30601271 | 0.81 | ASPH (0.44) | LMNAGAAALOX15ALDH1A1KDM4E | |
| SCHEMBL1536721 | 0.79 | PKM (0.54) | MAPTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30601261 | 0.79 | GAA (0.44) | MAPTHTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL1536635 | 0.78 | MAPT (0.41) | MAPTHTTLMNATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580429-B2 | Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2017-02-28 | — | — | US | disclosed |
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2015-04-09 | — | — | US | disclosed |
| US-8859568-B2 | Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-1824855-B1 | Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20110059996-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7829707-B2 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2010-11-09 | — | — | US | disclosed |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059996-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | MPO, EPX, XDH | MAPT 4038/4885HTT 3303/4885LMNA 2324/4885 |
| US-20150099769-A1 | PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | MPO, EPX, XDH | MAPT 4038/4885HTT 3280/4885LMNA 2133/4885 |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | MPO, EPX, SERPINB1 | MAPT 3973/4885HTT 3873/4885LMNA 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.